source
- Intellia reports positive Phase 3 readout for CRISPR gene-editing therapy in hereditary angioedemaIntellia Therapeutics announced that its CRISPR-based therapy achieved a successful readout in a Phase 3 trial for hereditary angioedema, a rare condition marked by sudden, potentially dangerous sw…
- Oruka’s experimental psoriasis drug achieves near-complete skin clearance in Phase 2 trialOruka Therapeutics reported that its experimental IL-23 inhibitor ORKA-001 cleared the skin of 40 of 63 patients (about 63%) in a Phase 2 study, achieving a PASI 100 response at 16 weeks. A further…